Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.44 |
| ▸ | HTR2A | P28223 | 10/20 | 0.44 |
| ▸ | HTR2C | P28335 | 10/20 | 0.44 |
| ▸ | HTR2B | P41595 | 10/20 | 0.44 |
| ▸ | DRD2 | P14416 | 9/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8610413 | 0.74 | NPSR1 (0.43) | LMNAHTTNPSR1L3MBTL1SIGMAR1 | |
| SCHEMBL9431991 | 0.72 | NPSR1 (0.40) | LMNAHTTNPSR1L3MBTL1SIGMAR1 | |
| SCHEMBL6251528 | 0.69 | SIGMAR1 (0.44) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL15700121 | 0.69 | LMNA (0.54) | LMNAHTTNPSR1L3MBTL1SIGMAR1 | |
| SCHEMBL8616201 | 0.67 | KDM4E (0.39) | LMNAHTTNPSR1L3MBTL1SIGMAR1 | |
| SCHEMBL6250064 | 0.65 | LMNA (0.49) | LMNAHTTNPSR1L3MBTL1SIGMAR1 | |
| SCHEMBL10925610 | 0.64 | SIGMAR1 (0.43) | LMNAHTTNPSR1L3MBTL1SIGMAR1 | |
| SCHEMBL15600621 | 0.63 | NPSR1 (0.54) | LMNAHTTNPSR1L3MBTL1SIGMAR1 | |
| SCHEMBL7937492 | 0.63 | NPSR1 (0.54) | LMNAHTTNPSR1L3MBTL1SIGMAR1 | |
| SCHEMBL7123284 | 0.63 | NPSR1 (0.54) | LMNAHTTNPSR1L3MBTL1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280779-B1 | NEW POLYCYCLIC INDANYLIMIDAZOLES WITH ALPHA2 ADRENERGIC ACTIVITY | ORION CORP (FI) | 2005-08-24 | — | — | EP | disclosed |
| EP-1280779-A1 | NEW POLYCYCLIC INDANYLIMIDAZOLES WITH ALPHA2 ADRENERGIC ACTIVITY | ORION CORPORATION (FI) | 2003-02-05 | — | — | EP | disclosed |
| US-6362211-B2 | FOR THERAPY OF NEUROLOGICAL, PSYCHIATRIC OR COGNITION DISORDER, DIABETES, LIPOLYTIC DISORDER, ORTHOSTATIC HYPOTENSION, OR SEXUAL DYSFUNCTION | ORION CORPORATION (FI) | 2002-03-26 | — | — | US | disclosed |
| US-20020013356-A1 | New polycyclic indanylimidazoles with alpha2 adrenergic activity | ORION CORPORATION (FI) | 2002-01-31 | — | — | US | disclosed |
| WO-2001085698-A1 | NEW POLYCYCLIC INDANYLIMIDAZOLES WITH ALPHA2 ADRENERGIC ACTIVITY | ORION CORPORATION (FI) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013356-A1 | New polycyclic indanylimidazoles with alpha2 adrenergic activity | ADRB2, ADRB1, ADRA1A | LMNA 1844/4885HTT 4500/4885NPSR1 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.